ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
NASDAQ:EPIX
Price:
6.95 USD
4.98%
Market Closed
Updated:
May 3, 2024
ESSA Pharma Inc
Research & Development
|
ESSA Pharma Inc
Research & Development Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Research & Development
-$21.3m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Research & Development
-$143.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Research & Development
-$131.8m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Research & Development
-$70.1m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$49.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-38%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ESSA Pharma Inc's Research & Development?
Research & Development
-21.3m
USD
-21.3m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Research & Development amounts to -21.3m USD.
What is ESSA Pharma Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-32%
-32%
Over the last year, the Research & Development growth was 10%. The average annual Research & Development growth rates for ESSA Pharma Inc have been -15% over the past three years , -32% over the past five years .
You don't have any saved screeners yet
